Physicians' Academy for Cardiovascular Education

GLP-1 RA & CVD

Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME

Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes

10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME

The cardiology challenge to manage CV risk in diabetes

10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD - Online CME

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark - Online CME

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom - Online CME

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

EBAC-accredited E-Learning

Online-CME - This course consists of 5 lectures.
This course consists of 5 lectures.

In this e-learning course, five important aspects of use of GLP-1RAs will be discussed. Member registration (free) is needed to enroll in this course.

Role of GLP-1RA in practice

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

How do GLP-1RAs work?

New - subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD
Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

Which patients to consider for GLP-1RA?

*NEW* Click on video for subtitling in English, German, Italian, Spanish, French, or Chinese.

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD
Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD
There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

There are barriers to intensify treatment in T2DM patients, leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

Expanding focus for cardiologists: The patient with diabetes and cardiovascular outcomes

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this e-learning course, the role of novel diabetes treatment approaches in the prevention of CVD in patients with T2DM will be discussed. Member registration (free) is needed to enroll in this course.

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD
Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.

Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

Click on video for subtitling in English, German, Italian, Spanish, French, Chinese

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.

Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?

Click on video for subtitling in English, German, Italian, Spanish, French, Chinese

10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME
Jorge Plutzky describes potential mechanisms for the benefit of some GLP1-RA in CVOTs and discusses their possible effects on diabetic atherosclerosis.

Jorge Plutzky describes potential mechanisms for the benefit of some GLP1-RA in CVOTs and discusses their possible effects on atherosclerosis in patients with diabetes.

Expert consensus on use of SGLT2i and GLP-1RAs for CV risk reduction in T2DM

News - Sep. 15, 2020

This 2020 expert consensus decision pathway (ECDP) provides practical guidance on the use of SGLT2i and GLP-1RAs for reducing the risk of CVD in patients with T2DM.

Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes

10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME
Prof. Landmesser discusses with professors Marx, Plutzky and Deanfield how to implement new therapies to reduce CV risk in patients with diabetes.

Prof. Landmesser discusses with professors Marx, Plutzky and Deanfield how to implement new therapies to reduce CV risk in patients with diabetes.

GLP-1 RA & CVD